121 related articles for article (PubMed ID: 17875318)
21. Significance of AF4-MLL reciprocal fusion in t(4;11) leukemias?
Sanders DS; Muntean AG; Hess JL
Leuk Res; 2011 Mar; 35(3):299-300. PubMed ID: 20952059
[No Abstract] [Full Text] [Related]
22. Activation of Ras-dependent Elk-1 activity by MLL-AF4 family fusion oncoproteins.
Ng MH; Ng RK; Kong CT; Jin DY; Chan LC
Exp Hematol; 2010 Jun; 38(6):481-8. PubMed ID: 20362031
[TBL] [Abstract][Full Text] [Related]
23. Complex MLL rearrangements in t(4;11) leukemia patients with absent AF4.MLL fusion allele.
Kowarz E; Burmeister T; Lo Nigro L; Jansen MW; Delabesse E; Klingebiel T; Dingermann T; Meyer C; Marschalek R
Leukemia; 2007 Jun; 21(6):1232-8. PubMed ID: 17410185
[TBL] [Abstract][Full Text] [Related]
24. Insights into the cellular origin and etiology of the infant pro-B acute lymphoblastic leukemia with MLL-AF4 rearrangement.
Bueno C; Montes R; Catalina P; Rodríguez R; Menendez P
Leukemia; 2011 Mar; 25(3):400-10. PubMed ID: 21135858
[TBL] [Abstract][Full Text] [Related]
25. Multistep pathogenesis of leukemia via the MLL-AF4 chimeric gene/Flt3 gene tyrosine kinase domain (TKD) mutation-related enhancement of S100A6 expression.
Yamaguchi H; Hanawa H; Uchida N; Inamai M; Sawaguchi K; Mitamura Y; Shimada T; Dan K; Inokuchi K
Exp Hematol; 2009 Jun; 37(6):701-14. PubMed ID: 19463771
[TBL] [Abstract][Full Text] [Related]
26. RNA-binding proteins of KHDRBS and IGF2BP families control the oncogenic activity of MLL-AF4.
Okuda H; Miyamoto R; Takahashi S; Kawamura T; Ichikawa J; Harada I; Tamura T; Yokoyama A
Nat Commun; 2022 Nov; 13(1):6688. PubMed ID: 36335100
[TBL] [Abstract][Full Text] [Related]
27. H3K79 methylation profiles define murine and human MLL-AF4 leukemias.
Krivtsov AV; Feng Z; Lemieux ME; Faber J; Vempati S; Sinha AU; Xia X; Jesneck J; Bracken AP; Silverman LB; Kutok JL; Kung AL; Armstrong SA
Cancer Cell; 2008 Nov; 14(5):355-68. PubMed ID: 18977325
[TBL] [Abstract][Full Text] [Related]
28. Proteomics-based strategy to identify biomarkers and pharmacological targets in leukemias with t(4;11) translocations.
Yocum AK; Busch CM; Felix CA; Blair IA
J Proteome Res; 2006 Oct; 5(10):2743-53. PubMed ID: 17022645
[TBL] [Abstract][Full Text] [Related]
29. Validation of an interphase fluorescence in situ hybridization approach for the detection of MLL gene rearrangements and of the MLL/AF9 fusion in acute myeloid leukemia.
Cavazzini F; Bardi A; Tammiso E; Ciccone M; Russo-Rossi A; Divona D; Lo Coco F; Hernandez JM; Wlodarska I; Hagemeijer A; Castoldi G; Cuneo A
Haematologica; 2006 Mar; 91(3):381-5. PubMed ID: 16503549
[TBL] [Abstract][Full Text] [Related]
30. Mixed lineage leukemia: roles in human malignancies and potential therapy.
Marschalek R
FEBS J; 2010 Apr; 277(8):1822-31. PubMed ID: 20236311
[TBL] [Abstract][Full Text] [Related]
31. Unraveling the Activation Mechanism of Taspase1 which Controls the Oncogenic AF4-MLL Fusion Protein.
Sabiani S; Geppert T; Engelbrecht C; Kowarz E; Schneider G; Marschalek R
EBioMedicine; 2015 May; 2(5):386-95. PubMed ID: 26137584
[TBL] [Abstract][Full Text] [Related]
32. Mll fusions generated by Cre-loxP-mediated de novo translocations can induce lineage reassignment in tumorigenesis.
Drynan LF; Pannell R; Forster A; Chan NM; Cano F; Daser A; Rabbitts TH
EMBO J; 2005 Sep; 24(17):3136-46. PubMed ID: 16096649
[TBL] [Abstract][Full Text] [Related]
33. The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis.
Luo RT; Lavau C; Du C; Simone F; Polak PE; Kawamata S; Thirman MJ
Mol Cell Biol; 2001 Aug; 21(16):5678-87. PubMed ID: 11463848
[TBL] [Abstract][Full Text] [Related]
34. Activated KRAS Cooperates with MLL-AF4 to Promote Extramedullary Engraftment and Migration of Cord Blood CD34+ HSPC But Is Insufficient to Initiate Leukemia.
Prieto C; Stam RW; Agraz-Doblas A; Ballerini P; Camos M; Castaño J; Marschalek R; Bursen A; Varela I; Bueno C; Menendez P
Cancer Res; 2016 Apr; 76(8):2478-89. PubMed ID: 26837759
[TBL] [Abstract][Full Text] [Related]
35. Mll-AF4 Confers Enhanced Self-Renewal and Lymphoid Potential during a Restricted Window in Development.
Barrett NA; Malouf C; Kapeni C; Bacon WA; Giotopoulos G; Jacobsen SEW; Huntly BJ; Ottersbach K
Cell Rep; 2016 Jul; 16(4):1039-1054. PubMed ID: 27396339
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-205 downregulates mixed-lineage-AF4 oncogene expression in acute lymphoblastic leukemia.
Dou L; Li J; Zheng D; Li Y; Gao X; Xu C; Gao L; Wang L; Yu L
Onco Targets Ther; 2013; 6():1153-60. PubMed ID: 24009426
[TBL] [Abstract][Full Text] [Related]
37. Use of Genome Engineering to Create Patient Specific MLL Translocations in Primary Human Hematopoietic Stem and Progenitor Cells.
Breese EH; Buechele C; Dawson C; Cleary ML; Porteus MH
PLoS One; 2015; 10(9):e0136644. PubMed ID: 26351841
[TBL] [Abstract][Full Text] [Related]
38. Differentiation of Acute Leukemia Cells Including Cells with MLL-AF4 Rearrangements Induced by Jiyuan Oridonin A.
Li X; Zhang F; Ke Y; Liu H; Hu Z; Wei L
Recent Pat Anticancer Drug Discov; 2024 Jan; ():. PubMed ID: 38204268
[TBL] [Abstract][Full Text] [Related]
39. Key morphologic changes and DNA strand breaks in human lymphoid cells: discriminating apoptosis from necrosis.
Fairbairn DW; Walburger DK; Fairbairn JJ; O'Neill KL
Scanning; 1996 Sep; 18(6):407-16. PubMed ID: 8819349
[TBL] [Abstract][Full Text] [Related]
40. Resistance of MLL-AFF1-positive acute lymphoblastic leukemia to tumor necrosis factor-alpha is mediated by S100A6 upregulation.
Tamai H; Miyake K; Yamaguchi H; Takatori M; Dan K; Inokuchi K; Shimada T
Blood Cancer J; 2011 Nov; 1(11):e38. PubMed ID: 22829076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
